Literature DB >> 8583139

Early perivenular fibrogenesis--precirrhotic lesions among moderate alcohol consumers and chronic alcoholics.

V Savolainen1, M Perola, K Lalu, A Penttilä, I Virtanen, P J Karhunen.   

Abstract

Cirrhosis is believed to be preceded by "precirrhotic" lesions indicating initial fibrogenesis in the perivenular area. We investigated three previously described markers of early perivenular fibrogenesis: the thickness of the rim of the terminal hepatic venule, perivenular fibrosis and perivenular fibronectin deposition. The frequencies of these features were evaluated and compared to long-term daily alcohol intake in autopsy series of 120 males comprising abstainers, moderate alcohol consumers and chronic heavy alcohol consumers. Thickening of the rim of the terminal hepatic venule showed no correlation to the long-term daily ethanol intake. In contrast, compared to abstainers, daily alcohol intake between 40 and 80 g for an average of 25 years was associated in an increased number of subjects with perivenular fibrosis (13.3% vs 38.9%, p < 0.05), and with perivenular fibronectin deposition (13.3% vs 44.4%, p < 0.025). Similarly, daily intake exceeding 80 g was associated in an increased number of subjects with perivenular fibrosis (56.1%, p < 0.001) and with perivenular fibronectin deposition (56.1%, p < 0.001). A daily intake exceeding 80 g (110 g/d vs 240 g/d) did not, however, further increase the occurrence of these lesions. A daily intake below 40 g of absolute alcohol was not associated with signs of early perivenular fibrogenesis. In this study, the frequencies of subjects with perivenular fibrosis and perivenular fibronectin deposition correlated with the amount of daily alcohol intake. A daily intake between 40 and 80 g was associated with approximately a three-fold and a daily intake exceeding 80 g with approximately a five-fold increase in the risk of these features. This could suggest that daily intake between 40 and 80 g represents a "threshold" level, beyond which the risk of alcoholic liver fibrosis increases significantly. The majority (50-70%) of chronic heavy alcohol consumers presented signs of early perivenular fibrogenesis, whereas cirrhosis was found in only 20% of heavy consumers. This could suggest that alcohol-induced fibrotic lesions of the liver may develop in the majority of people, but factors other than cumulative alcohol consumpation may have a critical impact on the progression of early liver fibrosis to cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583139     DOI: 10.1016/0168-8278(95)80057-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Hepatobiliary quiz-5 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-03

Review 2.  Outpatient management of alcohol-related liver disease.

Authors:  Douglas A Simonetto; Vijay H Shah; Patrick S Kamath
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05

3.  Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis.

Authors:  Archana Rastogi; Nayana Patil; Rakhi Maiwall; Chhagan Bihari; Ananda Soshee; Shiv K Sarin
Journal:  Virchows Arch       Date:  2021-04-02       Impact factor: 4.064

4.  High-throughput caveolar proteomic signature profile for maternal binge alcohol consumption.

Authors:  Jayanth Ramadoss; Wu-xiang Liao; Dong-bao Chen; Ronald R Magness
Journal:  Alcohol       Date:  2010-01-06       Impact factor: 2.405

5.  RNA interference against discoidin domain receptor 2 ameliorates alcoholic liver disease in rats.

Authors:  Zheng Luo; Huimin Liu; Xiaomeng Sun; Rong Guo; Ruibing Cui; Xiangxing Ma; Ming Yan
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

6.  Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease.

Authors:  Sophie Restellini; Nicolas Goossens; Sophie Clément; Nicolas Lanthier; Francesco Negro; Laura Rubbia-Brandt; Laurent Spahr
Journal:  World J Hepatol       Date:  2018-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.